A fusion protein for the prevention of streptococcus pneumoniae infection and its application
A novel fusion protein combining the C-terminal domain of pneumolysin and N-terminal domain of PhtD with an Fc domain and STABILON addresses the limitations of current vaccines by providing broad-spectrum protection and effective immunoprotection against Streptococcus pneumoniae.
WO2026045325A1 Publication Date: 2026-03-05NANJING CHENGSHI BIOMEDICAL TECH CO LTD
8 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/090122
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-27
- Filing Date
- 2025-04-21
- Publication Date
- 2026-03-05
AI Technical Summary
Technical Problem
Current pneumococcal vaccines have limited serotype coverage, high production costs, and are ineffective in infants and young children, with the emergence of non-vaccine serotypes due to the use of vaccines causing a problem of serotype substitution.
Method used
A novel fusion protein comprising the C-terminal domain of pneumolysin (ply) and the N-terminal domain of pneumococcal histidine triad protein PhtD, combined with an Fc domain and STABILON, is designed to provide broad-spectrum protection against Streptococcus pneumoniae infections.
Benefits of technology
The fusion protein demonstrates good immunogenicity, effectively preventing Streptococcus pneumoniae infections by inducing strong immune responses and reducing tissue lesions, as shown in mouse models.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a fusion protein, immunogenic composition, recombinant vaccine, and molecular architecture design and application, etc., for the prevention of Streptococcus Pneumoniae infection. The present invention starts from the protein molecular tertiary structures of ply and PhtD, and via creatively screening, the C-terminal domain of ply protein and the N-terminal domain of phtD protein are finally selected to construct a fusion protein, and the elements such as Fc domain and STABILON are further added. The fusion protein molecule of the present invention can weaken tissue lesions caused by Streptococcus Pneumoniae infection, has good immunogenicity, has an effective preventive and immunoprotective effect, and efficiently prevents Streptococcus Pneumoniae infection. The immunogenic composition, fusion protein, and recombinant vaccine for preventing Streptococcus Pneumoniae infection of the present invention have broad application prospects.
Need to check novelty before this filing date? Find Prior Art